Ruxience

USDailyMed:Rituximab AU:C L01FA01(WHO) AU:S4(Prescription only)CA:℞-only/ Schedule DUK:POM(Prescription only)US:℞-onlyEU:Rx-only 174722-31-7Y DB00073Y none 4F4X42SYQ6 D02994Y ChEMBL1201576N DTXSID5040910 Rituximab, sold under the brand nameRituxanamong others, is amonoclonal antibodymedication used to treat certainautoimmune diseasesand types ofcancer.It is used fornon-Hodgkin lymphoma,chronic lymphocytic leukemia,rheumatoid arthritis,granulomatosis with polyangiitis,idiopathic thrombocytopenic purpura,pemphigus vulgaris,myasthenia gravisandEpstein–Barr virus-positivemucocutaneous ulcers.It is given by slowintravenous infusion. The most common side effects with intravenous infusions are reactions related to the infusion (such as fever, chills and shivering) while most common serious side effects are infusion reactions, infections and heart-related problems.Similar side effects are seen when it is injected under the skin, with the exception of reactions around the injections site (pain, swelling and rash), which occur more frequently with the skin injections. Severe side effects include reactivation ofhepatitis Bin those previously infected,progressive multifocal leukoencephalopathy,toxic epidermal necrolysis, and death.It is unclear if use duringpregnancyis safe for the developing fetus or newborn baby. Rituximab is achimericmonoclonal antibodyagainst the proteinCD20, which is primarily found on the surface of immune systemB cells.When it binds to this protein it triggers cell death. Rituximab was approved for medical use in 1997.It is on theWorld Health Organization's List of Essential Medicines.Rituxan is co-marketed byBiogenandGenentechin the US, byRocheelsewhere except Japan, and co-marketed byChugai Pharmaceuticalsand Zenyaku Kogyo in Japan.